Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00265317
Status:
COMPLETED
Last Update Posted:
2013-02-06
First Post:
2005-12-12
Brief Title:
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 Sunitinib Is Better Than Erlotinib Alone
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Randomized Double-Blind Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SUN1058
Brief Summary:
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advancedmetastatic lung cancer who have received previous treatment with a platinum-based regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None